miércoles, 27 de noviembre de 2013

Today’s articles on Investing Ideas

Alpha-Rich Ideas

Quantum Fuel Systems: Inflection Point Has Been Reached, At Least 50% Upside Ahead
by Shaun Currie, CFA

Editor's notes: The move in Quantum Fuel Systems still has gas in the tank. Analyst Shaun Currie balances operating momentum against warrant dilution and sees substantial upside remaining.

InterContinental Hotels Group: Overlooked To Overbooked
by DAG1996

Editor's notes: IHG is well positioned for economic rebound and long-term growth. Wide moat, entry into growth markets, and high levels of profitability support 20% upside.

Gluskin Sheff + Associates Is On The Takeover Radar
by Brian Langis

Editor's notes: Canadian wealth manager GLUSF's attractive niche clientele combined with reasonable valuation make the stock an attractive takeover play. Firm has ~30% upside.

Guanwei Recycling: Valuation Looks Very Attractive
by Jonathan Verenger

Editor's notes: GPRC may be the baby thrown out with the bathwater: fears over Chinese companies have left the stock trading very cheaply. Lifting regulatory pressure could send the stock higher.

EXCO Resources: Fundamentals Remain Weak, Despite Leadership Change
by Richard Zeits

Editor's notes: XCO's stock price run-up belies the balance sheet and macro issues still facing the company. Energy expert Richard Zeits sees 30% downside.

Commtouch Software: A Return To Earnings Growth To Reward Investors
by Helix Investment Research

Editor's notes: A shift from the investment phase could propel Commtouch to be more closely valued with its peers. Helix Investment Research sees more than 55% upside.

AkzoNobel: Dutch Coating Company With Huge Upside
by McDuck Capital

Editor's notes: AKZOY has a durable economic moat with strong brands and good management. Value investor McDuck Capital sees 67% upside over the next two years.

Why Heska Could Double In 2014
by BuyTheDip SellTheRip

Editor's notes: Heska's competitive positioning suggests almost 100% potential upside, while its current bargain valuation makes it a low-risk addition to your portfolio.

WSP Holdings Will Reward Longs Soon
by Alpha Vulture

Editor's notes: Value investor Alpha Vulture takes the other side of the WH buyout, saying the evidence points towards a deal closing soon. 14% absolute return in a short period.

Pain Therapeutics: Very Substantial Risk-Adjusted Upside Vs. Downside
by Logical Thought

Editor's notes: Buysider Logical Thought crunches the numbers for Remoxy and PTIE and finds a promising result. Probability-weighted upside of 120%+ for the company as Pfizer reformulates the drug.

Autobytel A Potential Triple: 1x Sales For Double-Digit, Profitable Growth Is Rare
by Ravee Mehta

Editor's notes: ABTL's powerful lead generation will continue to drive its growth. As the market catches on, buysider Ravee Mehta sees 50% short-term upside with room for more over coming years.

Stocks Moving From Alpha-Rich Ideas

Monday, buysider Logical Thought said Pain Therapeutics offered 120%+ risk-adjusted upside, based on approval of its flagship drug Remoxy. The stock is +16.3% since. Read article »

On August 23, MBAvalueinvestor called Nuverra Environmental an over-levered "destroyer of capital," with 80% downside to its intrinsic value. Shares are -43.6% to date. Read article »

Breaking Alpha-Rich Ideas (for Pro Subscribers) Learn more »

Accelerated Adoption Of This Company's Technology Could Lead To 100% Upside by Inflection Point Investing LLC

You Should Be Very Excited About This Stock by Shaun Currie, CFA

This Company Has Become Too Cheap To Ignore by Paul Nouri

Individual Asset Valuation Points To 50% Upside At This Company by Street Smart Investor

Long Ideas

Sunshine Heart: Potential '10 To 100 Bagger' Revisited - Part II by Robert Honeywill

SAEXploration: Bull Response To The Bear Case (My Variant Point Of View) by Mike Winston

LeapFrog Is Top On My Christmas Wishlist by Big Alpha Research

Energy Fuels: Miner Turned Broker by Jim Wallingford

Time Warner Cable: What's It Really Worth In Any M&A Deal With Comcast And Charter? by Mycroft

DelMar Pharmaceuticals: 2 Major Near-Term Catalysts May Lift Share Price Dramatically by Grant Zeng

Don't Think Cisco Is Cheap? You Haven't Looked At The Balance Sheet by Charles Patton

Medium-Term Opportunity - 35% Upside With Key Energy Services by Marwood Media

Should You Still Buy Frontier Communications At $4.67? by Achilles Research

Enormous Growth Prospects For Salesforce.com by Blackstone Equity Research

Is This The Next High-Grade, Low-Cost Silver Producer? by Steve Nicastro

FedEx: Should You Still Buy At $138? by Achilles Research

Overblown Geopolitical Risks Make TransGlobe Energy A Compelling Investment by David Tristan Liu

Intel TV Flop Is Huge For Investors by Rizzi Capital

Spherix: A Longer Timeline Than Perceived, Significant IP Holdings by Tom Shaughnessy

Lightstream Resources - Two Options To Eliminate Debt And Potentially Triple Its Share Price by Devon Shire

Upside Still Exists In Broadridge Financial Solutions by Austin Guy

Boston Therapeutics: A Speculative Biopharmaceutical Company With Promise by The Behavioral Economist

4 Reasons To Buy BP by Chris Lau

Yoho Resources: 2013 Reserve Report Reinforces Why I Am Long by Michael Fitzsimmons

JCP: Ullman's Buy Is Very Meaningful by Dante's Investing Ideas

2 Deep Value Stocks With Excellent Fundamentals by Aram Durphy

Xerox: Emerging As A Leading Services Company by Joseph Harry

Berkshire Is Worth $120 by Seeking Profits

Cisco: Cheaper Than A Junk Bond by Seeking Profits

Seaspan Secondary Sends Share Price To Snipe Land by Investor RockieK

New Hepatitis C Drug Success Should Drive Gilead Sciences In 2014 by James Banjo

Bull Of The Day: Raytheon by Zacks Investment Research

AstraZeneca: A Positive Future Awaits This Company by Balanced Investing

Ignore Lions Gate Sell-Off, Stock Looks Good Long Term by Gary Bourgeault

GlaxoSmithKline: What's The Next Growth Driver? by Cristina Tov

Facebook - Growth Company/Laggard Stock by Adrian McCarroll

Ventrus Bio Poised For Run-Up Into Second Round Of Phase III Results by Mike Havrilla

NanoString Technologies: An Emerging Growth Play In Molecular Diagnostics by Rod Raynovich

Bullish On Bear Creek Mining by Itinerant

Dumpster Diving: Is J.C. Penney Worth A Gamble? by SmartStops

Natural Grocers Still Looks Like An Unnatural Growth Opportunity by Stephen Simpson, CFA

Teva Pharmaceutical Industries: What Others Are Not Seeing by Balanced Investing

No Worries With American Tower by Marsha Robe

Sony: The Return To Glory Is Only A Few (Large) Steps Away by Zach Cunningham

Cynapsus Therapeutics: A Significantly Undervalued Parkinson's Play by Jason Napodano

From 'Mad Men' To Social Media: What Twitter's IPO Says About Today's Advertising by Barrett Ehrlich

Chimerix: A Significant Player In The Antiviral Therapeutics Market by Biomed Group

Can Delta Airlines Take Investors' Returns To New Heights? by Gabe Ortt

Profit From The 'Death Boom' With Service Corp International (SCI) by Austin Guy

Yellow Media Up Over 100% YTD, 100%+ To Run by Glen Bradford

Tesla And The Ford Pinto: How Media Coverage Can Shape Perception And Derail Mass Market Adoption by Elephant Analytics

Plains All American: Why This MLP Looks Appealing by Gabe Ortt

Is American Axle Trading At A Discount To Its Intrinsic Value? by Investing Insight

Why Authentidate's Management Is Bullish by Lazarus Investment Partners

Qualcomm Risk Rises In ParkerVision Case by Robert Kassel

4 Reasons Why MGT Capital Is Dramatically Undervalued by Samuel Rae

Facebook Success Rides On Knowledge Economy by Tom Genot

Get Exposure To China's Growing Auto Market And Online Advertising by ONeil Trader

ModernGraham Valuation: Bemis Company by Benjamin Clark

Senvest: Better Than Buffett And Einhorn... At A Discount by Alpha Exposure

Canadian Solar Is Looking Strong In 2014 by Robert Dydo

Intel: Should You Buy, Hold, Sell Or Short The Stock? by Mycroft

Quantum: A CNG Tanks And Fuel Systems Company On The Verge Of A Turnaround by Sarfaraz A. Khan

Bank Of America Is Breaking Out by Bret Jensen

For J.C. Penney, Investors May Achieve A Bank Of America Style Recovery by Ian Agar

Myriad Genetics' Share Price May Soon Challenge 52-Week High by J.J. McGrath

Invesco Presents Investors With Ideal Entry Point by Equity Watch

NACCO Industries: After Spin-Off This Underfollowed Conglomerate Trades At A Sizeable Discount by Bram de Haas

Ariad Pharma Appears Cheap Despite Reduced Opportunity by David Eller

Why The Fresh Market May Get Cheap Enough To Lure Contrarians by Xin He

ESSA Bank & Trust: One Dollar Of Value Available For 50 Cents by Gregory Vousvounis

Pandora Competing With iTunes Radio by Sramana Mitra

Sirius XM Battles OnStar by Rizzi Capital

Invest In Emerging Markets With Dentists And Dentsply International by Chris Katje

The Best Way To Play Natural Gas As A Transportation Fuel by Elliott Gue

Chelsea Therapeutics: Primed For An Easy Double by Bob's Stocks

Why Is Opko Falling? by Stock Whisper

Short Ideas

Herbalife Could Damn Well Be The Next MBIA by Quoth the Raven

Tesla: Hope Is Not A Strategy. We Have Seen This Bubble Movie Before by Unhedge

The Bon-Ton Stores: Get Out Before It Hits The Clearance Aisle by Micro and Small Cap Reporter

Memo To Apple: Prepare For Weak Holiday Sales by Kofi Bofah

Camtek: Printing A 3D Pump And Dump by Tom Shaughnessy

NQ Mobile: Extremely Overhyped Even When Ignoring All Signs Of Fraud by Goldbaum Research

Quick Picks & Lists

3 Of The Most Overpriced Stocks With Real Downside Risk by Jae Jun

Dassault Systemes: Short-Term Buying Opportunity For Long-Term Growth by Kevin Greenhalgh

Celsion Prepares For Phase III Trial Redux by Quoth the Raven

This Is How To Invest In Wind Energy by Kapitall

Yum Brands - Puzzled Behind Deutsche Bank's Timing And Aggressive Price Target by The Value Investor

ModernGraham Valuation Of Chubb Corp. by Benjamin Clark

Where To Find Bargains In Over-Extended Equity Markets by BubbleBustInvesting

Life Sciences Offer Good Growth With Much Less Risk Than Biopharmaceuticals by Intrepid Investor

Alcoa - On The Verge Of Trading Above $10 Following Goldman's Bullish Notes by The Value Investor

'Greed Is Good': Hologic Attracts The Value Crowd by PropThink

3 More Low Cost Small Cap Gold Producers That Will Survive Now And Thrive Later by Ben Kramer-Miller

Cramer's Picks

Cramer's Mad Money - 4 Battleground Stocks (11/26/13) by SA Editor Miriam Metzinger

Cramer's Lightning Round - I Can't Take The Pain In Vale (11/26/13) by SA Editor Miriam Metzinger

Fund Holdings

Tile Shop: SAC Capital Stake, Motive Theory And Internal Conflicts In Gotham's Thesis by GS Analytics

Insider Ownership

Storm Resources: 6 Different Insiders Have Purchased Shares This Month by Markus Aarnio

IPO Analysis

Prepare Now For The Automotive TrueCar IPO by Don Dion

Vince: Premium Price For This Luxury Offering by The Value Investor

4 IPOs Deliver Strong Market Debuts On Friday by Renaissance Capital IPO Research

U.S. IPO Recap: Chinese IPOs Continue Their Strong Run by Renaissance Capital IPO Research


Why are you receiving this? You subscribed to Investing Ideas at Seeking Alpha.
Unsubscribe from this email or manage all your Seeking Alpha email choices here.

To ensure you receive these emails in the future, please add account@seekingalpha.com to your address book, contacts or list of safe senders.

Sent by Seeking Alpha, 345 7th Ave. Suite 1400 New York, NY 10001

No hay comentarios:

Publicar un comentario